$IQST
iQSTEL Inc Stock $iqst

$iqst Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000166357723000398 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$39.76M	$32.82M
YoY Change	81.24%	38.5%
Cost Of Revenue	$38.73M	$32.04M
YoY Change	87.81%	40.2%
Gross Profit	$1.029M	$784.5K
YoY Change	-21.78%	-7.3%
Gross Profit Margin	2.59%	2.39%
Selling, General & Admin	$860.0K	$953.1K
YoY Change	-19.67%	-12.01%
% of Gross Profit	83.62%	121.49%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$30.00K	$34.43K
YoY Change	3.99%	19.47%
% of Gross Profit	2.92%	4.39%
Operating Expenses	$957.8K	$1.037M
YoY Change	-23.75%	-9.37%
Operating Profit	$70.75K	-$252.7K
YoY Change	20.3%	-15.25%
Interest Expense	$10.00K	$126.2K
YoY Change	-371.0%	-3385.68%
% of Operating Profit	14.13%
Other Income/Expense, Net	-$24.84K	$91.07K
YoY Change	-21.13%	615.93%
Pretax Income	$50.00K	-$161.6K
YoY Change	83.07%	-43.37%
Income Tax
% Of Pretax Income
Net Earnings	-$62.01K	-$213.9K
YoY Change	-9.95%	-39.08%
Net Earnings / Revenue	-0.16%	-0.65%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.01	$0.00
COMMON SHARES
Basic Shares Outstanding	166.4M shares	164.2M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.000M	$1.127M
YoY Change	54.44%	-31.54%
Cash & Equivalents	$2.001M	$1.127M
Short-Term Investments
Other Short-Term Assets	$890.0K	$35.04K
YoY Change	62.96%	-92.9%
Inventory	$27.12K	$28.12K
Prepaid Expenses	$1.697M	$571.4K
Receivables	$7.636M	$4.945M
Other Receivables	$1.230M	$962.9K
Total Short-Term Assets	$11.79M	$7.098M
YoY Change	91.95%	4.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$463.0K	$473.5K
YoY Change	18.19%	22.45%
Goodwill	$5.172M	$5.172M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$156.4K	$54.47K
YoY Change	-62.17%	-87.23%
Total Long-Term Assets	$6.336M	$6.254M
YoY Change	4.26%	2.78%
TOTAL ASSETS
Total Short-Term Assets	$11.79M	$7.098M
Total Long-Term Assets	$6.336M	$6.254M
Total Assets	$18.12M	$13.35M
YoY Change	48.34%	3.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.015M	$2.702M
YoY Change	109.82%	7.35%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$180.0K	$253.5K
YoY Change
Long-Term Debt Due	$252.8K	$251.2K
YoY Change	-371.21%	161.18%
Total Short-Term Liabilities	$9.914M	$6.912M
YoY Change	257.91%	91.62%
LONG-TERM LIABILITIES
Long-Term Debt	$91.02K	$102.4K
YoY Change	-10.41%	-2.31%
Other Long-Term Liabilities	$160.0K	$159.3K
YoY Change	10.44%	6.57%
Total Long-Term Liabilities	$246.9K	$261.8K
YoY Change	0.18%	2.91%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.914M	$6.912M
Total Long-Term Liabilities	$246.9K	$261.8K
Total Liabilities	$10.16M	$7.174M
YoY Change	236.85%	85.78%
SHAREHOLDERS EQUITY
Retained Earnings	-$25.96M	-$25.08M
YoY Change	33.05%	29.0%
Common Stock	$170.2K	$164.7K
YoY Change	12.12%	8.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.528M	$6.843M
YoY Change
Total Liabilities & Shareholders Equity	$18.12M	$13.35M
YoY Change	48.34%	3.48%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$62.01K	-$213.9K
YoY Change	-9.95%	-39.08%
Depreciation, Depletion And Amortization	$30.00K	$34.43K
YoY Change	3.99%	19.47%
Cash From Operating Activities	$290.0K	-$918.6K
YoY Change	-640.94%	-6.99%
INVESTING ACTIVITIES
Capital Expenditures	$30.00K	$69.00K
YoY Change	-176.39%	-409.42%
Acquisitions
YoY Change
Other Investing Activities	-$30.00K	-$67.14K
YoY Change	-87.99%	-95.71%
Cash From Investing Activities	-$60.00K	-$136.1K
YoY Change	-79.24%	-91.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	660.0K	400.0K
YoY Change
NET CHANGE
Cash From Operating Activities	290.0K	-918.6K
Cash From Investing Activities	-60.00K	-136.1K
Cash From Financing Activities	660.0K	400.0K
Net Change In Cash	890.0K	-654.7K
YoY Change	-359.8%	-74.57%
FREE CASH FLOW
Cash From Operating Activities	$290.0K	-$918.6K
Capital Expenditures	$30.00K	$69.00K
Free Cash Flow	$260.0K	-$987.6K
YoY Change	-1913.11%	2.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
	IQST	Weighted Average Remaining Life Of Warrants Granted In Period WeightedAverageRemainingLifeOfWarrantsGrantedInPeriod
	dei	Entity Central Index Key EntityCentralIndexKey	0001527702
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2022Q2	IQST	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss1 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss1		usd
	IQST	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss1 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss1		usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
	us-gaap	Asset Acquisition Consideration Transferred Other Assets AssetAcquisitionConsiderationTransferredOtherAssets		usd
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes		usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions		usd
	IQST	Stock Issued During Period Value Acquisitions To Be Issued StockIssuedDuringPeriodValueAcquisitionsToBeIssued		usd
	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue		usd
CY2023Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
CY2022Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
	IQST	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Increased By Vwap Outstanding Weighted Average Remaining Life ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIncreasedByVWAPOutstandingWeightedAverageRemainingLife
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
	IQST	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms Of Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOfForfeited
	us-gaap	Dividends Dividends		usd
CY2022	us-gaap	Dividends Dividends		usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives		usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives		usd
	IQST	Revaluation Of Derivative Liabilities RevaluationOfDerivativeLiabilities		usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-55984
	dei	Entity Registrant Name EntityRegistrantName	iQSTEL Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-2808620
	dei	Entity Address Address Line1 EntityAddressAddressLine1	300 Aragon Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 375
	dei	Entity Address City Or Town EntityAddressCityOrTown	Coral Gables
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33134
	dei	City Area Code CityAreaCode	954
	dei	Local Phone Number LocalPhoneNumber	951-8191
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	166382571	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1126770	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1329389	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4944938	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4209125	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	28119	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	26124	usd
CY2023Q2	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	426529	usd
CY2022Q4	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	326324	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	571360	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	545628	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	7097716	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6436590	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	473534	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	401021	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	99592	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	99592	usd
CY2023Q2	us-gaap	Goodwill Goodwill	5172146	usd
CY2022Q4	us-gaap	Goodwill Goodwill	5172146	usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	454704	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	440135	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	54469	usd
CY2023Q2	us-gaap	Assets Assets	13352161	usd
CY2022Q4	us-gaap	Assets Assets	12549484	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2702104	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2254636	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2660369	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2482352	usd
CY2023Q2	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	26613	usd
CY2022Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	26613	usd
CY2023Q2	us-gaap	Loans Payable Current LoansPayableCurrent	251215	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	94342	usd
CY2023Q2	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	243759	usd
CY2022Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	235949	usd
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	253476	usd
CY2023Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	774954	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1357787	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6912490	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6451679	usd
CY2023Q2	us-gaap	Loans Payable To Bank LoansPayableToBank	102418	usd
CY2022Q4	us-gaap	Loans Payable To Bank LoansPayableToBank	108150	usd
CY2023Q2	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	159344	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	154238	usd
CY2023Q2	us-gaap	Liabilities Liabilities	7174252	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6714067	usd
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1200000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1200000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	164656688	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	164656688	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	161595511	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	161595511	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	164657	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	161595	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	31791446	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	31136120	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-25081525	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24504395	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-31226	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-33557	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6843383	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	6759794	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	-665474	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-924377	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6177909	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5835417	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13352161	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12549484	usd
CY2023Q2	us-gaap	Revenues Revenues	32824829	usd
CY2022Q2	us-gaap	Revenues Revenues	23699716	usd
	us-gaap	Revenues Revenues	57491358	usd
	us-gaap	Revenues Revenues	43119027	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	32040363	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	22853442	usd
	us-gaap	Cost Of Revenue CostOfRevenue	55490156	usd
	us-gaap	Cost Of Revenue CostOfRevenue	41788693	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	784466	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	846274	usd
	us-gaap	Gross Profit GrossProfit	2001202	usd
	us-gaap	Gross Profit GrossProfit	1330334	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1037184	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1144452	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2571450	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2133950	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1037184	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	1144452	usd
	us-gaap	Operating Expenses OperatingExpenses	2571450	usd
	us-gaap	Operating Expenses OperatingExpenses	2133950	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-252718	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-298178	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-570248	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-803616	usd
CY2023Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	4264	usd
CY2022Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	10125	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	519	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	-4628	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-39355	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6432	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-73209	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	16780	usd
CY2023Q2	IQST	Interest Expense2 InterestExpense2	20103	usd
CY2022Q2	IQST	Interest Expense2 InterestExpense2	3836	usd
	IQST	Interest Expense2 InterestExpense2	20103	usd
	IQST	Interest Expense2 InterestExpense2	18724	usd
CY2023Q2	IQST	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss1 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss1	146268	usd
	IQST	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss1 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss1	342575	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	91074	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	12721	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	249782	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6572	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-161644	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-285457	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-320466	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-810188	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-161644	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-285457	usd
	us-gaap	Profit Loss ProfitLoss	-320466	usd
	us-gaap	Profit Loss ProfitLoss	-810188	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	52301	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	65723	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	256664	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	95962	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-213945	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-351180	usd
	us-gaap	Net Income Loss NetIncomeLoss	-577130	usd
	us-gaap	Net Income Loss NetIncomeLoss	-906150	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-161644	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-285457	usd
	us-gaap	Profit Loss ProfitLoss	-320466	usd
	us-gaap	Profit Loss ProfitLoss	-810188	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	-2993	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	1023	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	-4570	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	1407	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-158651	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-286480	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-315896	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-811595	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	53767	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	65222	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	258903	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	95273	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-212418	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-351702	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-574799	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-906868	usd
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023Q2	IQST	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	164636688	shares
CY2022Q2	IQST	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	150835665	shares
	IQST	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	164346860	shares
	IQST	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	149196728	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	6759794	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	400000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11230	usd
CY2023Q1	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	240258	usd
CY2023Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	804	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-363185	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	7048901	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6900	usd
CY2023Q2	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	1527	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-213945	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6843383	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	7416911	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1000000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	41139	usd
CY2022Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-196	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-554970	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	7902884	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	30490	usd
CY2022Q2	IQST	Stock Issued During Period Value Acquisitions To Be Issued StockIssuedDuringPeriodValueAcquisitionsToBeIssued	1550000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	325000	usd
CY2022Q2	IQST	Common Stock Payable Value CommonStockPayableValue	18900	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	500000	usd
CY2022Q2	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-522	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-351180	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	9975572	usd
	us-gaap	Profit Loss ProfitLoss	-320466	usd
	us-gaap	Profit Loss ProfitLoss	-810188	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	18130	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	90529	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	68488	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	62371	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	7226	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	7407	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-342575	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	589928	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	910284	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1995	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	75867	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6977	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-46631	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-47832	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1144422	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	49794	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-675466	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	34224	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-721400	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1435292	usd
	us-gaap	Asset Acquisition Consideration Transferred Other Assets AssetAcquisitionConsiderationTransferredOtherAssets	-1564132	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	132249	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	47223	usd
	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	149537	usd
	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	1000	usd
	us-gaap	Proceeds From Payments For Long Term Loans For Related Parties ProceedsFromPaymentsForLongTermLoansForRelatedParties	2700	usd
	us-gaap	Proceeds From Payments For Long Term Loans For Related Parties ProceedsFromPaymentsForLongTermLoansForRelatedParties	100	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-279086	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1612255	usd
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	150000	usd
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	9006	usd
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	232018	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1100000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	400000	usd
	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	250000	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	500000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	790994	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1367982	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6873	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-9311	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-202619	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1688876	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1329389	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3334813	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1126770	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1645937	usd
	us-gaap	Interest Paid Net InterestPaidNet	6600	usd
	us-gaap	Interest Paid Net InterestPaidNet	3333	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	325000	usd
	IQST	Stock Issued During Period Value Acquisitions To Be Issued StockIssuedDuringPeriodValueAcquisitionsToBeIssued	1550000	usd
	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	240258	usd
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2011-06-24
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zaDVTxvzExT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Use of Estimates</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	364883	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1057650	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	-729091	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	-656629	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	473534	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	401021	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	68488	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	62371	usd
CY2023Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	153918	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	120139	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	14040	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	26600	usd
CY2023Q1	us-gaap	Advance Payments Netted Against Claim Receivable AdvancePaymentsNettedAgainstClaimReceivable	21000	usd
CY2022Q4	us-gaap	Advance Payments Netted Against Claim Receivable AdvancePaymentsNettedAgainstClaimReceivable	21000	usd
CY2023Q1	us-gaap	Income Tax Receivable IncomeTaxReceivable	402	usd
CY2022Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	389	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	362000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	357500	usd
CY2023Q1	us-gaap	Security Deposit SecurityDeposit	20000	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	20000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	571360	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	545628	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1202625	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	202492	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	353633	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	202492	usd
CY2023Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	251215	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	94342	usd
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	102418	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	108150	usd
CY2023Q2	us-gaap	Loans Payable LoansPayable	243759	usd
CY2022Q4	us-gaap	Loans Payable LoansPayable	235949	usd
CY2023Q2	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	243759	usd
CY2022Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	235949	usd
	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p id="xdx_80B_eus-gaap--DerivativesReportingOfDerivativeActivity_zDwDHUYjJYp7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 8 – WARRANTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On April 5, 2022, we entered into a Common Stock Purchase Option Agreement with Apollo Management Group, Inc (Holder) to subscribe for and purchase from the Company, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220405__20220405__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_zekeJxaVP5V7">4,800,000</span> shares of Common Stock with an exercise price per share of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220405__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_zJeq68LgB6Ch">$2.00</span>; and an initial exercisable date on <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20220405__20220405__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_zV37IPjQiaR8">September 30, 2022</span>. The purchase price of this option was <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20220405__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_zUA7WBmcWwne">$500,000</span>. The Company determined that the warrants had a fixed monetary value with a variable number of shares at inception and categorized the warrants as a liability in the accompanying consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_900_eus-gaap--OptionIndexedToIssuersEquitySettlementAlternatives_c20220405__20220405__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_zlA8Xrf8pmXk">The Holder and the Company agreed that the Holder had the right and the obligation to exercise, on a cashless basis, $1,000,000 of the Options not later than October 15, 2022</span>. Thereafter, the Holder shall undertake to exercise not less than (i) <span id="xdx_90B_eus-gaap--WarrantsNotSettleableInCashFairValueDisclosure_iI_c20221114_zj7nWeoFkJC3">$400,000</span> of the Options on a “cash basis” not later than the later of (y) <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20221114__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_z46n1ae8iiW2">November 14, 2022</span> or (z) the date on which there is an effective registration statement permitting the issuance of the Option Shares to or resale of the Option Shares by the Holder and (ii) an additional <span id="xdx_905_eus-gaap--OptionIndexedToIssuersEquitySettlementAlternativesCashAtFairValue_iI_c20221214__us-gaap--DebtInstrumentAxis__custom--ApolloOptionAdditionalMember_zGTV9rsQ7lh9">$400,000</span> of the Options on a “cash basis” not later than the latest of (x) thirty (30) days following the exercise of the Option under subsection (i), above, (y) December 14, 2022, or (z) the date on which there is an effective registration statement permitting the issuance of the Option Shares to or resale of the Option Shares by the Holder. From and after the occurrence of the three above-referenced exercises, each additional exercise of Options hereunder shall be in an amount not less than <span id="xdx_90D_eus-gaap--OptionIndexedToIssuersEquitySettlementAlternativesCashAtFairValue_iI_c20221214__us-gaap--DebtInstrumentAxis__custom--ApolloOptionEachAdditionalMember_zDbXD1j00hq7">$200,000</span> and exercised only on a cash basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_90A_eus-gaap--DebtInstrumentCallFeature_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ApolloManagementGroupMember_zpbbaEaQCM5l">The Holder’s obligation to exercise each specified portion of this option on the specific dates above is subject to the volume-weighted average price (“VWAP”, market value), being not less than $0.20 per share on the relevant option exercise date. Adjusted option shares at VWAP of $0.20 shall be 48,000,000 shares</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of activity regarding warrants issued as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zZyZlAg5zEd1" style="font: 11pt Calibri, Helvetica, Sans-Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - NOTE 8 - WARRANTS - Schedule of Warrant Summary (Details)"> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1pt"> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Warrants</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Contractual life (in years)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; padding-left: 5.4pt">Outstanding, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20221231_z8jbiBZOS6wd">23,112,575</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20221231_zXFLSdpAPjgj">0.17</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231_z83QmXhcgfkf">0.75</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20230630_zPgobWEEmWE8"><span style="-sec-ix-hidden: xdx2ixbrl0915">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230630_z9St3rcfbUXc"><span style="-sec-ix-hidden: xdx2ixbrl0916">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_ecustom--WeightedAverageRemainingLifeOfWarrantsGrantedInPeriod_d0_c20230101__20230630_zzirXUkD9xMj"><span style="-sec-ix-hidden: xdx2ixbrl0917">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Increase in number of warrants by VWAP</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_c20230101__20230630_zqtP6paHshx2">5,262,465</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--IncreaseInNumberOfWarrantsWeightedAverageExercisePrice_c20230101__20230630_zUdKv8LGDHze">0.14</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIncreasedByVWAPOutstandingWeightedAverageRemainingLife_d0_c20230101__20230630_zvBOmRI7ojmj"><span style="-sec-ix-hidden: xdx2ixbrl0920">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230630_zQ5qYYZHZb33">2,941,177</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20230630_zxz00cy1GX47">0.14</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230630_zNIA3S46R0Q8">0.70</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 5.4pt">Forfeited/canceled</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20230630_zQ0hkj6ePXA7"><span style="-sec-ix-hidden: xdx2ixbrl0924">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20230630_zU4Z7utA3Ppb"><span style="-sec-ix-hidden: xdx2ixbrl0925">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOfForfeited_d0_c20230101__20230630_zIaCPM1wMRfh"><span style="-sec-ix-hidden: xdx2ixbrl0926">— </span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt">Outstanding, June 30, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20230630_zD8gnLb0EEJl">25,433,863</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20230630_zIqNYYFYG9xc">0.14</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230630_z7yX7t2Te1E5">0.25</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
CY2022Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	400000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	23112575	shares
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.17
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P0Y9M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease	5262465	shares
	IQST	Increase In Number Of Warrants Weighted Average Exercise Price IncreaseInNumberOfWarrantsWeightedAverageExercisePrice	0.14
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	2941177	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.14
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P0Y8M12D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	25433863	shares
CY2023Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.14
CY2023Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P0Y3M
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	161595511	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	161595511	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0467	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0543	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0006	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0473	pure
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	1357787	usd
	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	240258	usd
	us-gaap	Debt Securities Held To Maturity Transfer Derivative Hedge Gain Loss DebtSecuritiesHeldToMaturityTransferDerivativeHedgeGainLoss	342575	usd
CY2023Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	774954	usd
	IQST	Revaluation Of Derivative Liabilities RevaluationOfDerivativeLiabilities	342575	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	342575	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	120000	shares
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	18130	usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	400000	usd
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	164656688	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	164656688	shares
CY2023Q2	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	426529	usd
CY2022Q4	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	326324	usd
CY2023Q2	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	26613	usd
CY2022Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	26613	usd
	us-gaap	Management Fee Expense ManagementFeeExpense	288000	usd
	us-gaap	Management Fee Expense ManagementFeeExpense	270000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	18130	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	71629	usd
CY2023Q2	us-gaap	Financial Guarantee Insurance Contracts Risk Management Activities Mitigating Claim Liabilities Accrued Liabilities FinancialGuaranteeInsuranceContractsRiskManagementActivitiesMitigatingClaimLiabilitiesAccruedLiabilities	129627	usd
CY2022Q4	us-gaap	Financial Guarantee Insurance Contracts Risk Management Activities Mitigating Claim Liabilities Accrued Liabilities FinancialGuaranteeInsuranceContractsRiskManagementActivitiesMitigatingClaimLiabilitiesAccruedLiabilities	79628	usd
CY2023Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
	us-gaap	Operating Lease Expense OperatingLeaseExpense	2137	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	38645	usd
CY2023Q2	us-gaap	Revenues Revenues	32824829	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	32040363	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	784466	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1037184	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-252718	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	91074	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-161644	usd
CY2022Q2	us-gaap	Revenues Revenues	23699716	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	22853442	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	846274	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1144452	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-298178	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	12721	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-285457	usd
	us-gaap	Revenues Revenues	57491358	usd
	us-gaap	Cost Of Revenue CostOfRevenue	55490156	usd
	us-gaap	Gross Profit GrossProfit	2001202	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2571450	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-570248	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	249782	usd
	us-gaap	Profit Loss ProfitLoss	-320466	usd
	us-gaap	Revenues Revenues	43119027	usd
	us-gaap	Cost Of Revenue CostOfRevenue	41788693	usd
	us-gaap	Gross Profit GrossProfit	1330334	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2133950	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-803616	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6572	usd
	us-gaap	Profit Loss ProfitLoss	-810188	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	7097716	usd
CY2023Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	6254445	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6912490	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	261762	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6436590	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	6112894	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6451679	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	262388	usd

Files In Submission

Name	View Source	Status
0001663577-23-000398-index-headers.html	Edgar Link	pending
0001663577-23-000398-index.html	Edgar Link	pending
0001663577-23-000398.txt	Edgar Link	pending
0001663577-23-000398-xbrl.zip	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
iqst-20230630.xsd	Edgar Link	pending
iqst10q_063023.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
iqst-20230630_lab.xml	Edgar Link	unprocessable
iqst-20230630_pre.xml	Edgar Link	unprocessable
iqst-20230630_cal.xml	Edgar Link	unprocessable
iqst-20230630_def.xml	Edgar Link	unprocessable
iqst10q_063023_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IQST
iQSTEL Inc Stock $iqst

2023 Q3 Form 10-Q Financial Statement

#000166357723000398 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IQST iQSTEL Inc Stock $iqst

2023 Q3 Form 10-Q Financial Statement

#000166357723000398 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IQST
iQSTEL Inc Stock $iqst